Surgical Sectioning for Tethered Cord Syndrome
(OCCULT Trial)
Trial Summary
What is the purpose of this trial?
This trial is testing whether a surgery to cut a small piece of tissue at the end of the spinal cord is better than standard medical treatments for patients with Occult Tethered Cord Syndrome (OTCS). These patients often do not find relief from typical treatments. The surgery aims to relieve pressure and tension in the spinal cord, which may help improve their symptoms. This surgical method is currently the most widely accepted treatment for OTCS.
Do I need to stop my current medications for the trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of the treatment for tethered cord syndrome?
Is the surgical sectioning of the filum terminale generally safe?
Surgical sectioning of the filum terminale is generally considered safe, but there is a risk of nerve injury and retethering (the spinal cord becoming tethered again) after the procedure. Using special monitoring during surgery can help reduce nerve injury, and certain techniques may help prevent retethering.12367
How is the treatment 'Release of filum terminale' unique for tethered cord syndrome?
The 'Release of filum terminale' is a surgical procedure specifically designed to address tethered cord syndrome by cutting the filum terminale (a thread-like structure in the spine) to relieve tension on the spinal cord, which is different from other treatments that may not directly target the source of the tethering.89101112
Research Team
Jeffrey Greenfield, MD, PhD
Principal Investigator
Weill Medical College of Cornell University
Eligibility Criteria
This trial is for people aged 2 to 79 with Occult Tethered Cord Syndrome (OTCS) who haven't improved after at least a year of medical treatment. They must score at least 30 on the OCCULT Grading Scale. It's not for those with visible signs of spinal issues, previous lumbar spine or spinal dysraphism surgeries, or a history of central nervous system infections or autoimmune diseases.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants are randomized to either surgical untethering of the filum terminale or medical management
Follow-up
Participants are monitored for safety and effectiveness after treatment
Crossover
Subjects in the medical management arm may cross over to the surgical arm if deemed beneficial
Treatment Details
Interventions
- Release of filum terminale (Procedure)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Weill Medical College of Cornell University
Lead Sponsor
Dr. Robert Min
Weill Medical College of Cornell University
Chief Executive Officer since 2024
MD, MBA
Dr. Adam R. Stracher
Weill Medical College of Cornell University
Chief Medical Officer since 2024
MD